subpage banner

 

Overview

Overview

Corporate Summary

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Presentations

April 2024

Corporate Presentation

Q2 2024

Investor Factsheet

Stock
information

Stock Data

GANX

NASDAQ: GANX

Market Price: $3.15
Day's Range: $3.10 - $3.27
Volume: 57,038.00
Last Update: 2024-04-17

 

Stock Chart